Adrienne Tymiak, Executive Director of Bioanalytical and Discovery Analytical Sciences at BMS, leads a scientific team focused on technologies that advance drug Discovery and Development, spanning biomarker discovery from ‘omics through to targeted quantitation, molecular spectroscopy and physico-chemical characterization of xenobiotic drugs and endogenous molecules. She served in a variety of scientific and strategic leadership roles for Discovery, Pharmaceutical Development and Translational Research, contributing to major technology, informatics, process, capital infrastructure and organizational design projects as well as to global collaborations with academic and industrial partners. Adrienne has extensive experience leading drug discovery and GxP bioassay development, natural products isolation and structure determination, implementation of open access analytical platforms such as NMR, LCMS and chiral separations capabilities for Discovery chemists and establishing the characterization standards for all preclinical drug candidates from small molecules through proteins and other treatment modalities in the BMS portfolio. Adrienne is recognized as an expert in biopharma applications of analytical technologies and has been a member of ACS, ASMS, AAPS and Sigma Xi, and serves on the boards of directors for the IQ Consortium and the Allotrope Foundation (since its inception). She has chaired the Princeton chapter of the ACS and has served as a reviewer for analytical and bioanalytical chemistry journals, NIH study sections and, most recently, the NCI Cancer Moonshot. Over her career, Adrienne has been a frequently invited speaker at national and international conferences with more than 90 external presentations and posters, over 65 peer reviewed publications, 9 book chapters and 3 patents.